Condition: Myeloid Leukemia, Philadelphia Positive · Sponsor: Novartis Pharmaceuticals
The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib from adult to pediatric patients will be conducted. Full extrapolation is based on the concept that CML in the pediatric population has the same pathogenesis, similar clinical characteristics and progression pattern as in adults.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Indiana UH Riley H for CIU | Indianapolis, Indiana, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| University of Mississippi Medical Center | Jackson, Mississippi, United States | Recruiting |
| Columbia University Medical Center New York Presbyterian | New York, New York, United States | Recruiting |
| Cinn Children Hosp Medical Center | Cincinnati, Ohio, United States | Recruiting |
| Childrens Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| Uni Of Texas MD Anderson Cancer Ctr | Houston, Texas, United States | Recruiting |
| University Of Utah | Salt Lake City, Utah, United States | Recruiting |
| Novartis Investigative Site | Hangzhou, Zhejiang, China | Recruiting |
| Novartis Investigative Site | Beijing, China | Recruiting |
| Novartis Investigative Site | Shanghai, China | Recruiting |
| Novartis Investigative Site | Tianjin, China | Recruiting |
+ 27 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04925479